A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

September 9, 2025

Study Completion Date

October 24, 2025

Conditions
Type 2 Diabetes
Interventions
DRUG

Cagrilintide

Participants will receive once-weekly cagrilintide subcutaneously.

DRUG

Semaglutide

Participants will receive once-weekly semaglutide subcutaneously.

DRUG

Placebo

Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.

Trial Locations (50)

1827

Lenasia Clinical Trial Centre, Lenasia

7760

Ashmed Medi-Centre, Cape Town

9301

Oraderumaz (Pty) Ltd, Bloemfontein

11050

Healthcare centre Zvezdara, Belgrade

18000

Healthcare centre Nis, Niš

19000

Policlinic for diabetes, Zaječar

20110

Manassas Clinical Research Center, Manassas

23606

TPMG Clinical Research, Newport News

27514

University of North Carolina, Chapel Hill

33155

Bioclinical Research Alliance, Miami

34000

Healthcare centre Kragujevac, Kragujevac

37203

Clinical Research Associates, Nashville

48532

Elite Research Center, Flint

50266

Iowa Diab & Endo Res Center, West Des Moines

75230

Velocity Clinical Res-Dallas, Dallas

77061

Synergy Groups Medical, Houston

77079

PlanIt Research, PLLC, Houston

83646

Solaris Clinical Research, Meridian

89128

Palm Research Center Inc., Las Vegas

91325

Valley Clinical Trials, Inc., Northridge

93401

DIA - KONTROL s.r.o., Levice

210011

The Second Affiliated Hospital of Nanjing Medical University-Endocrinology, Nanjing

The Second Affiliated Hospital of Nanjing Medical University_Nanjing, Nanjing

212001

The Affiliated Hospital of Jiangsu University-Endocrinology, Zhenjiang

250013

Jinan Central Hospital, Ji'nan

Jinan Central Hospital Affiliated to Shandong University, Jinan

475000

Huaihe Hospital of Henan University-Endocrinology, Kaifeng

Huaihe Hospital of Henan University, Kaifeng

060-0062

Manda Memorial Hospital_Internal Medicine, Sapporo-shi, Hokkaido

242-0004

Tsuruma Kaneshiro Diabetes Clinic, Yamato-shi

116-0012

Kumanomae Nishimura Internal Medical Clinic, Arakawa-ku, Tokyo

260-0804

Akaicho Clinic, Chiba-shi, Chiba

819-0006

Futata Tetsuhiro Clinic Meinohama_Internal medicine, Fukuoka-shi, Fukuoka

819-0168

Kunisaki Makoto Clinic, Fukuoka-shi, Fukuoka

062-0007

Sasaki Internal Medicine, Hokkaido

311-0113

Naka Kinen Clinic_Internal medicine, Ibaraki

235-0045

H.E.C Science Clinic, Kanagawa

606-8507

Kyoto University Hospital, Kyoto-shi, Kyoto

311-4153

Minami Akatsuka Clinic, Mito-shi, Ibaraki

103-0027

Tokyo-Eki Center-building Clinic_Internal Medicine, Tokyo

Tokyo-Eki Center-building Clinic, Tokyo

104-0031

Fukuwa Clinic_Internal Medicine, Tokyo

125-0054

Kato Clinic of Internal Medicine_Internal Medicine, Tokyo

18 000

University Clinical Centre Nis, Niš

077 01

MOMED, s.r.o, Kráľovský Chlmec

901 01

SIN AZUCAR s.r.o., Malacky

979 01

ENRIN, s.r.o., Rimavská Sobota

05201

LUDIA, s. r. o., Spišská Nová Ves

0002

Prinshof Medical Campus, Pretoria

0186

Clinical Trial Systems (CTC), Pretoria

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT06323161 - A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin | Biotech Hunter | Biotech Hunter